Tech Company Financing Transactions
Telum Therapeutics Funding Round
On 7/1/2026, Telum Therapeutics secured $20.5 million in Series A funding from AMR Action Fund, CDTI and Clave.
Transaction Overview
Company Name
Announced On
7/1/2026
Transaction Type
Venture Equity
Amount
$20,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead program targeting hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Plaza Cein, Noáin, Chartered Community of Navarre
Navarra, 31110
Spain
Navarra, 31110
Spain
Phone
Website
Email Address
Overview
Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Engineered Phage Lytic Proteins as new antimicrobial products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Subhendu Basu
Chief Operating Officer
Roberto Díez
Chief Scientific Officer
Diana Gutiérrez
VP - Product Management
Verónica Alcolea
VP - Regulatory Affairs
Irene de Miguel
VP - Regulatory Affairs
Amy Fix
Browse more venture capital transactions:
Prev: 7/1/2026: Twelve Labs venture capital transaction
Next: 7/1/2026: Appnigma AI venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs